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Non-Hodgkin lymphoma of T-cell lineage involving the breast is rare. We report on a
41-year-old woman with T-cell lymphoblastic lymphoma who presented with multiple
bilateral breast masses. The patient was treated with intensive chemotherapy and med-
iastinal and whole-brain irradiation. She remains in complete remission 24 months after
diagnosis. The clinical, histologic, phenotypic, and cytogenetic features are described,
with a review of the literature. Am. J. Hematol. 80:216–222, 2005. ª 2005 Wiley-Liss, Inc.
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INTRODUCTION
Lymphoblastic lymphoma (LBL) is a high-grade
lymphoma that represents 2–4% of all adult non-
Hodgkin lymphomas (NHLs) in Western countries
[1,2]. Most cases are of T-cell lineage (80–85%), and
occur in adolescents and young adult males [3]. The
typical presentation is of a rapidly growing mediast-
inal mass associated with pleural and pericardial effu-
sions and B symptoms. Most patients present with
advanced stage (III/IV) disease, and bone marrow
involvement occurs in 30–50% of cases [3,4]. Other
common sites of involvement include the peripheral
lymph nodes (usually supradiaphragmatic), central
nervous system (CNS), spleen, liver, and gonads [3,4].
Since T-cell LBL (T-LBL) has many similarities
with T-cell acute lymphoblastic leukemia (T-ALL),
many investigators consider T-LBL and T-ALL dif-
ferent manifestations of the same disease [4]. T-ALL
comprises 25% of adult ALL cases, and is more
common in young males [5]. T-ALL patients typically
present with involvement of the bone marrow and
peripheral blood, but a mediastinal mass is often
present. The distinction between T-LBL and T-ALL
is arbitrary: patients with>25% of blasts in the bone
marrow are deemed to have ALL [3]. Despite simila-
rities between T-ALL and T-LBL, distinct phenotypic
and cytogenetic differences have been described, sug-
gesting the presence of distinct subtypes within the
two entities [3].
T-LBL is an aggressive NHL with a 5-year survival
of 26% [2]. Complete remission (CR) and disease-free
survival (DFS) rates have improved significantly in
the past few years with the use of intensive multiagent
chemotherapy, including CNS prophylaxis, similar to
that used for T-ALL.
We present a case of T-LBL presenting as bilateral
breast masses associated with a previously unreported
balanced reciprocal translocation t(3,11)(q21;
p12–13). The clinical, histologic, phenotypic, and
genetic features are presented, with a review of the
literature.
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CLINICAL SUMMARY
A 41-year-old Afro-Caribbean woman, without any
significant past medical history, noted bilateral breast
lumps in October 2002. She denied any associated
symptoms, including fever, night sweats, and weight
loss. Clinical evaluation in January 2003 revealed mul-
tiple masses in both breasts, but no axillary, cervical,
or inguinal lymphadenopathy was detected. A chest
radiograph and abdominal and pelvic ultrasonography
were normal. Her blood counts, calcium, erythrocyte
sedimentation rate (ESR), lactic dehydrogenase (LDH),
and uric acid were all within normal limits. Bilateral
breast biopsies were performed, and a diagnosis of
‘‘nodular, small cleaved-cell’’ NHL was rendered. She
was referred to our hospital for further evaluation and
treatment.
On presentation, she was found to have bilateral,
multiple, firm, and nontender breast nodules, varying
in size from 1–3 cm. Physical examination was other-
wise normal, as were her blood counts, LDH, and
calcium levels. A serologic test for human T-cell leu-
kemia virus (HTLV)-I was negative. Mammography
(Fig. 1a) detected six masses measuring 2.6 cm in
greatest dimension in the left breast, and seven masses
measuring 3.3 cm in greatest dimension in the right
breast. A computed tomography (CT) scan (Fig. 1b)
of the neck, chest, abdomen, and pelvis showed soft-
tissue opacities in the superior anterior mediastinum
and in the inferior posterior mediastinum, as well as
an enlarged 2-cm right internal mammary lymph
node. A positron emission tomography (PET) scan
(Fig. 1c) demonstrated bilateral uptake in the breast,
mediastinum, and retroperitoneum. Bilateral exci-
sional breast biopsies demonstrated multiple, dense,
nodular, and diffuse infiltrates of T-lymphoblasts,
but a staging marrow biopsy was negative.
The patient was considered to have stage III T-
LBL, for which she was treated according to the
protocol of the German Multicenter Study Group
for ALL (GMALL) [6], which included systemic and
intrathecal chemotherapy as well as mediastinal and
whole-brain radiation therapy. Treatment was com-
plicated by an episode of disseminated herpes zoster
for which she was hospitalized and received intrave-
nous acyclovir. She also required extensive transfu-
sion and growth-factor support. Upon completion of
therapy, there was no evidence of disease on physical
Fig. 1. Imaging studies pre- and posttreatment. a: Pretreatment mammogram shows bilateral nodular breast masses
(arrowheads, large masses in inferior quadrants). b: Pretreatment CT scan demonstrates breast and mediastinal disease
(arrowheads). c: Pretreatment PET scan shows increased uptake of radiotracer in breast and mediastinum (arrowheads).
Posttreatment mammogram (d), CT (e), and PET scans (f) show no evidence of disease.
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examination, mammography, CT, or PET scans
(Fig. 1d–f). She remains in clinical and radiographic
remission 12 months after completion of treatment.
MATERIALS AND METHODS
Hematoxylin and eosin (HE) and immunohisto-
chemical (IHC) stains were performed on 3-mm for-
malin-fixed, paraffin-embedded tissue sections. The
following antibodies were used for IHC analysis:
CD3, CD8, CD20, CD79a, bcl-6, Ki-67, ALK-1,
CD99 (DakoCytomation, Carpinteria, CA), CD2,
CD4, CD5, CD7, CD30, CD57 (Novocastra, Burlin-
game, CA), CD43, bcl-2 (Biogenex, San Ramon,
CA), p53, TIA-1 (Immunotech, Westbrook, ME),
TdT (Supertech, Bethesda, MD), and panCK (AE1/
AE3, Boehringer Mannheim, Indianapolis, IN). The
DakoCytomation Envision Plus System (DakoCyto-
mation) was used for detection. In situ hybridization
(ISH) was performed using a probe for Epstein-Barr
virus (EBV)-encoded viral RNAs (EBER 1–2, Ven-
tana, INFORM EBER, Tucson, AZ).
Three-color flow cytometric analysis (FACScan,
Becton Dickinson, San Diego, CA) was performed
on the breast biopsy tissue, using Cell Quest software
(Becton Dickinson) according to standard proce-
dures. T-, B-, natural killer (NK)-cell, and myeloid
lineage antigens were analyzed, using a comprehen-
sive panel of monoclonal antibodies.
Polymerase chain reaction (PCR) for the T-cell
receptor (TCR)-g gene and immunoglobulin heavy
chain (IgH) gene rearrangements was performed on
fresh tissue, as previously described [7,8].
PCR to detect HTLV-I and -II was also performed
on fresh tissue, using primers to amplify a 268-bp
sequence of the HTLV-I and -II gag gene and a 148-
bp sequence of the HTLV-I tax gene (unpublished
protocol). HTLV-II DNA and DNA from a known
HTLV-I-associated T-cell lymphoma were used as
positive controls.
G-banding was performed on metaphases obtained
from overnight (12–15 hr) unstimulated cultures, using
standard procedures. Twelve cells were karyotyped and
reported according to the International System for
Human Cytogenetic Nomenclature (ISCN) 1995 [9].
RESULTS
Excisional biopsies of the right and left breast
masses showed a dense, vaguely nodular, and diffuse
lymphoid infiltration of the breast parenchyma, with
extension into mammary fat (Fig. 2a). The infiltrate
was composed of lymphocytes showing a spectrum
from small cells with round nuclei and coarse chroma-
tin to medium and focally large-sized cells with fine
stippled chromatin, indistinct nucleoli, and scant cyto-
plasm, consistent with lymphoblasts. Numerous mi-
totic figures and foci of single-cell necrosis were
identified. Lymphoblasts infiltrated between the acini,
expanding the lobules, in a lobulocentric pattern.
Occasional foci of epithelial infiltration by the lympho-
blasts, forming lymphoepithelial lesions (LELs), were
highlighted with a pan-cytokeratin stain (Fig. 2b). The
adjacent uninvolved breast parenchyma showed mild
fibrosis and lobular sclerosis.
The lymphoblasts were TdT+ (Fig. 3c), CD99+,
CD3+ (Fig. 3a), CD7+, and focally CD5+, but did
not express CD2 (Fig. 3b), CD4, or CD8 (‘‘double
negative’’ (DN) T-cells). A moderate infiltrate of small
reactive CD4+ T-cells was also present. The blasts
expressed CD43 and bcl-2, and approximately 50%
showed faint cytoplasmic staining with CD79a (Fig.
3d) as well as weak staining for CD30. The Ki-67 label-
ing index was virtually 100%, and nuclear p53 staining
Fig. 2. Morphologyof breast T-LBL. a:Mixednodular (‘‘lobulo-
centric’’)anddiffusepatternoflymphoblastinfiltration(HE, ·50).
b: Lymphoepithelial lesion (HE, ·200) highlighted by staining
withpan-cytokeratin (inset,·400). [Color figurecanbeviewed in
the online issue, which is available at www.interscience.
wiley.com.]
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was seen in up to 20% of blasts. No staining was seen
with CD34, CD20, bcl-6, ALK-1, TIA-1, and CD56,
and in situ hybridization for EBER was negative.
Flow cytometry confirmed the presence of an imma-
ture (TdT+) population of medium-sized cells with dim
CD45 expression, cytoplasmic (but absent surface) CD3,
andvariableCD117,HLA-DR,CD30,andCD79a(cyto-
plasmic) expression. Blasts were negative for CD34,
CD1a, CD10, CD16 + 56, CD25, CD13, CD33, and
myeloperoxidase (MPO). No surface expression of the
TCRa/b, TCRg/d, or Ig heavy chains was identified.
IHC staining of the bone marrow biopsy and flow
cytometric analysis of the marrow aspirate showed no
evidence of disease.
PCR for TCR-g and IgH gene rearrangements
demonstrated clonal and polyclonal products, respec-
tively. Absence of HTLV-I and -II DNA was con-
firmed by PCR analysis. Karyotypic analysis of
lymphoblasts showed a t(3;11)(q21;p12–13) translo-
cation in 5 of 12 cells analyzed (Fig. 4).
DISCUSSION
NHLs of the breast are uncommon, comprising
between 0.04–0.5% of all malignant breast neoplasms
in most series, and 1.7–2.2% of extranodal NHLs in
Western countries [10]. The majority of breast NHLs
are of B-cell phenotype, with the frequency of T-cell
NHLs ranging from 2.5–7.5% [11–14]. Several types
of T-cell NHL have been reported in the breast,
including anaplastic large-cell lymphoma, peripheral
T-cell lymphoma not otherwise specified (NOS),
adult T-cell lymphoma/leukemia (ATLL), and NK/
T-cell lymphoma [15,16].
Involvement of the breast by T-LBL is unusual. A
search of the literature yielded 9 cases (Table I), includ-
ing 2 single case reports [17,18] and 7 patients included
in larger series [11–13,19,20]. In an additional 2 cases
of LBL reported in the earlier literature, no data
regarding B- or T-cell lineage was provided [21]. Breast
involvement by T-ALL (not included in Table I), albeit
infrequent, has also been reported [22]. Furthermore,
since previously published reports of T-LBL provided
inadequate histologic and phenotypic characterization,
Fig. 3. IHC staining of T-LBL (·200) a: Lymphoblasts show cytoplasmic CD3 staining. b: CD2 staining highlights reactive
T-cells, but lymphoblasts are negative. c: Majority of lymphoblasts express TdT. d: Weak cytoplasmic CD79a expression
in lymphoblasts; cells with intense staining (arrows) represent scattered, admixed, mature B-cells. [Color figure can be
viewed in the online issue, which is available at www.interscience.wiley.com.]
Fig. 4. Partial G-band karyotype of T-LBL.
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it has not been possible to distinguish between T-LBL
and T-ALL in a few cases.
Based on the limited clinical information available,
it appears that all the reported patients were young
women (17–30 years old) who had a dismal outcome,
all of the patients dying of disease a maximum of 14
months after diagnosis (Table I). Only one patient [17]
treated with CHOP, intrathecal methotrexate, and cra-
nial radiotherapy followed by maintenance therapy
with 6-mercaptopurine and methotrexate achieved
complete remission. However, this patient relapsed
after 4 months and died 12 months after diagnosis.
There is considerable emphasis in the literature on
the distinction between primary and secondary NHLs
of the breast. Although some authors define primary
breast NHLs as those that present in the breast [18],
most authors reserve that term for lymphomas when
there is no evidence of disease outside the breast. The
published cases of T-LBL, where information was
provided [13,17,18,20], all appeared to be secondary,
since there was evidence of disease outside the breast
at time of presentation. In our patient, there was
evidence of mediastinal disease as well as retroperito-
neal adenopathy on staging workup. Thus, although
the true site of origin cannot be assigned unequivo-
cally, lymphatic dissemination to the breast from a
mediastinal primary is likely.
Our patient presented with multiple breast masses.
NHLs of the breast typically present as a unilateral
mass; the frequency of bilateral disease at presenta-
tion ranges from 5–25% [10]. Among previous
reports of T-LBL in which adequate clinical detail
was provided, 2 of 5 patients presented with bilateral
masses [12,20]. One patient [12] was a 22-year-old
woman who presented with bilateral breast lym-
phoma postpartum, similar to reports of Burkitt lym-
phomas of the breast in women of childbearing age.
The latter is thought to be due to expression of pro-
lactin receptors by the lymphoma cells [23]. Prolactin
receptors are also expressed on DN thymocytes [24],
but the exact role of these receptors in lymphoblast-
trafficking to the breast is not known.
The histology of previously reported T-LBL cases
is not described in any significant detail. Yumuk et al.
[17] described diffuse infiltration of the breast by
lymphoblasts in their case of T-LBL in leukemic
phase. In our patient, there was a predominantly
nodular (lobulocentric) pattern (Fig. 2a), and LELs
were also present (Fig. 2b). The latter have been
reported for other types of breast lymphomas [11–
13], including one case of T-LBL [11].
The lymphoblasts of our patient were CD34,
TdT+, CD2, CD3(cyt)+, CD5(partial)+, CD7+,
CD4, CD8, CD25, surface TCRa/b and TCRg/
d, and demonstrated a clonal rearrangement of the
TCRg gene. This profile suggests that the neoplasm
originated from an early thymic T-cell precursor
population, resembling the DN2/pro-T2 stage of nor-
mal thymocyte development [25], most likely in the
mediastinum, with subsequent spread to the breasts.
Expression of CD117 but absent Bcl-6 expression is
also consistent with an early T-cell precursor origin of
the blasts. Bcl-6 expression is less often observed in T-
LBL with a DN phenotype [26], while CD117 is
known to play a role in early thymocyte (DN stage)
development [27]. CD117 expression was reported in
up to 40% of patients with T-ALL/LBL [28], and is
more commonly seen in cases with the most immature
phenotypes [29]. Expression of CD13, a non-T-
restricted marker, is often observed in CD117+ T-
LBLs [29], probably reflecting a prethymic precursor
phenotype. The lack of CD13 and CD34 expression
in our case is consistent with the phenotype of T-
lineage-committed thymic lymphoblasts [30].
The lymphoblasts in our case expressed CD79a and
CD99. Up to 52% of T-LBLs express CD79a [31], a
TABLE I. Reported Cases of T-LBL Involving Breast*
Age
(years) Stage IHC profile
Survival after
diagnosis (months) Treatment CNS prophylaxis References
20 IVa CD3+ 12 CHOP Yes 17
30 IV CD3+, CD45RO+ 14 CHOP + RT No 20
20 IV CD45RO+ 0b Cytoxan, methotrexate,
vincristine, adriamycine
N/A 18
17 III CD45RO+, CD4+, CD8+ 12 Chemo,cRT N/A 13
41 III See Results 24 Chemo (GMALL protocol),
RT (brain, mediastinum)
Yes Present case
*Five additional reported cases had absent or limited phenotype, and clinical information was not provided [11,12,19].
RT, radiotherapy; N/A, not available.
aBone marrow and peripheral blood were involved, and patient had hepatomegaly; reported as ‘‘leukemic’’ phase of T-LBL.
bPatient died of sepsis during treatment.
cRegimen not specified.
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subunit of the B-cell antigen receptor complex, ori-
ginally thought to be a specific marker of normal and
neoplastic B cells. Moreover, CD79a expression
appears to be restricted to DN T-LBLs [31] and is
of lower intensity compared to B cells, as also
observed in our case (Fig. 3d). CD99 is expressed in
80–90% of T-LBLs [32], and appears to correlate
with TdT expression [33]. In the thymus, CD99 is
expressed at high levels not only in very early T-line-
age cells but also in CD4+CD8+ or double-positive
(DP) thymocytes [34]. The function of this protein at
the early DN stage of development is not known, but
a role in the mediation of apoptosis of maturing (DP)
thymocytes was demonstrated [35].
Expression of CD30 by neoplastic lymphoblasts,
albeit at a weak level, is unusual. CD30 expression
in T-LBLs was reported to be negative [3], though
one study found expression of a variant CD30 iso-
form in 3 of 14 T-ALL cases [36]. In the normal
thymus, CD30 is expressed in the medulla and is
thought to play a role in negative selection [37].
Among T-cell lymphomas, CD30 expression is char-
acteristic of anaplastic large-cell lymphoma, but was
also described in several cases of ATLL, where it was
linked to HTLV provirus integration [38]. We ruled
out the possibility of an association with HTLV in
our case, since a serologic test as well as PCR for
HTLV DNA were both negative.
Chromosomal abnormalities in T-LBL are similar
to those described for T-ALL. Commonly occurring
translocations juxtapose the regulatory regions of
TCR genes, located at chromosomes 14q11, 7q32–36,
and 7p15, with proto-oncogenes, usually transcription
factors, that include Tal1, Tal2, Lyl1, Lom2, and Lck
[4]. Intriguingly, some of these transcription factors
are expressed in early (DN) thymocytes [39], and the
oncogenic fusion transcripts are thought to cause dys-
regulated growth and maturation arrest of the lym-
phoblasts. Other chromosomal translocations, not
involving the TCR genes, were also reported in T-
LBL [40,41]. Cytogenetic analysis of our case showed
a t(3;11)(q21;p12–13) translocation (Fig. 4), which
was not previously reported in T-LBL. Since the reso-
lution of the G-band karyotype was not optimal, the
breakpoint on chromosome 11p could not be deter-
mined with accuracy. It is notable, however, that one
of the oncogenes implicated in T-ALL/LBL pathogen-
esis, Lom2, is located at chromosome 11p13.
Treatment of T-LBL with CHOP-like regimens has
not been very effective, with CR rates between 50–
71% and DFS rates between 23–53% at 5 years [4].
Intensive chemotherapy regimens, including CNS
prophylaxis, similar to those used for T-ALL,
resulted in improved CR rates (77–95%) and DFS
rates of 45–67% at 5 years [4,6]. Mediastinal recur-
rence has been one of the most common causes of
failure, resulting in the adoption of mediastinal irra-
diation in more recent protocols [42]. The GMALL
protocol includes mediastinal irradiation, and was
associated with a 93% CR rate and 62% DFS at 7
years [6]. In the GMALL report, the probability of
survival was higher in patients with stage I/II disease
(83% survival at 4 years) compared to those with
stage III/IV disease (48% survival at 4 years) [6].
Previous studies found that high LDH, stage IV dis-
ease, marrow involvement, B symptoms, CNS invol-
vement, and age older than 40 years is associated with
a worse prognosis [4]. Our patient had stage III dis-
ease with a normal LDH level, no B symptoms, and
no CNS or bone marrow involvement.
In conclusion, we report on a highly unusual case
of T-LBL presenting as bilateral, multinodular, lobu-
locentric breast masses that was successfully treated
with intensive chemotherapy, CNS prophylaxis, and
mediastinal irradiation. Our report represents the first
detailed immunohistochemical, flow cytometric, cyto-
genetic, and molecular analysis of a T-LBL present-
ing in the breast.
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